{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3%25+Sodium+Chloride",
    "query": {
      "intervention": "3% Sodium Chloride"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2279,
    "total_pages": 228,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3%25+Sodium+Chloride&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-22T20:27:05.550Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07052903",
      "title": "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Transthyretin Amyloidosis With Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Nucresiran",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1750,
      "start_date": "2025-07-02",
      "completion_date": "2032-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 45,
      "location_summary": "La Jolla, California • Laguna Hills, California • Stanford, California + 38 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07052903"
    },
    {
      "nct_id": "NCT05224141",
      "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab/Vibostolimab Co-Formulation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 460,
      "start_date": "2022-03-24",
      "completion_date": "2027-06-07",
      "has_results": true,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 11,
      "location_summary": "Mobile, Alabama • Los Angeles, California • Boca Raton, Florida + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05224141"
    },
    {
      "nct_id": "NCT04973137",
      "title": "A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Light Chain (AL) Amyloidosis"
      ],
      "interventions": [
        {
          "name": "Birtamimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Standard of Care Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Prothena Biosciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2021-08-30",
      "completion_date": "2025-06-20",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 22,
      "location_summary": "North Haven, Connecticut • Trumbull, Connecticut • Washington D.C., District of Columbia + 16 more",
      "locations": [
        {
          "city": "North Haven",
          "state": "Connecticut"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04973137"
    },
    {
      "nct_id": "NCT06264596",
      "title": "Epinephrine in Irrigation Fluid for Visualization During Ankle Surgery",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intraoperative Bleeding"
      ],
      "interventions": [
        {
          "name": "Epinephrine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline irrigation fluid",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The Guthrie Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-08",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 1,
      "location_summary": "Sayre, Pennsylvania",
      "locations": [
        {
          "city": "Sayre",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06264596"
    },
    {
      "nct_id": "NCT02641639",
      "title": "FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Platinum Resistant Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Fosbretabulin tromethamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mateon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 70,
      "start_date": "2016-06",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641639"
    },
    {
      "nct_id": "NCT00910039",
      "title": "Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cognitive/Functional Effects",
        "Metastatic Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        },
        {
          "name": "cognitive assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2009-04",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-29",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • Cleveland, Ohio",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910039"
    },
    {
      "nct_id": "NCT07140939",
      "title": "A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subcutaneous Fat"
      ],
      "interventions": [
        {
          "name": "CBL-514 Injection",
          "type": "DRUG"
        },
        {
          "name": "0.9% Sodium Chloride",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Caliway Biopharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2026-09-01",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 11,
      "location_summary": "Encinitas, California • West Palm Beach, Florida • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Hunt Valley",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07140939"
    },
    {
      "nct_id": "NCT03136406",
      "title": "QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "avelumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aNK for Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ETBX-011",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GI-4000",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2017-08-11",
      "completion_date": "2019-11-01",
      "has_results": true,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 1,
      "location_summary": "El Segundo, California",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03136406"
    },
    {
      "nct_id": "NCT06901531",
      "title": "A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer",
        "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastric Adenocarcinoma or Cancer",
        "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "zolbetuximab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid (leucovorin or local equivalent)",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil (5-FU)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2025-05-22",
      "completion_date": "2028-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 37,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Cerritos, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06901531"
    },
    {
      "nct_id": "NCT03583606",
      "title": "A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Disease",
        "Immunisation"
      ],
      "interventions": [
        {
          "name": "ChAd3-EBO-Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA Multi-Filo Ebola Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-11-12",
      "completion_date": "2020-01-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-09-22T20:27:05.550Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583606"
    }
  ]
}